Core Viewpoint - The announcement highlights that China Resources Double Crane Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Double Crane Limin Pharmaceutical (Jinan) Co., Ltd., has successfully passed the GMP compliance inspection, which is crucial for maintaining product quality and production capacity in the pharmaceutical market [1][6]. Group 1: GMP Inspection Information - The GMP compliance inspection was conducted from April 22 to April 25, 2025, at the new solid preparation workshop for tablet and hard capsule production [1]. - The investment for the new solid preparation workshop was approximately RMB 260 million (unaudited) [1]. Group 2: Product and Market Overview - The solid preparation workshop produces two key products: Nifedipine controlled-release tablets and Levofloxacin hydrochloride capsules [2][3]. - Nifedipine controlled-release tablets have a projected sales revenue of RMB 147 million for 2024, with a market share of 3.10% for Double Crane Limin among 28 approved manufacturers in China [5][6]. - Levofloxacin hydrochloride capsules are part of a competitive market with 62 approved manufacturers, and the total sales for 2024 are estimated at RMB 392 million [6]. Group 3: Impact on the Company - The successful GMP compliance inspection is expected to enhance the company's ability to maintain stable product quality and production capacity, thereby meeting market demand [6]. - The inspection results are not anticipated to have a significant impact on the company's overall performance [6].

Core Viewpoint - China Resources Double Crane (600062) announced that its wholly-owned subsidiary, China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd., passed the GMP compliance inspection conducted by the Shandong Provincial Drug Administration, covering the production workshops for tablets and hard capsules [1] Group 1: Company Developments - The GMP inspection included the production lines for tablets and hard capsules in the newly established solid preparation workshop No. 6 [1] - The investment for the new solid preparation workshop No. 6 amounted to 260 million yuan [1] Group 2: Financial Performance - The projected sales revenue for the company's Nifedipine sustained-release tablets in 2024 is 147 million yuan [1] - The sales revenue for Levofloxacin hydrochloride capsules is estimated to be 23.3137 million yuan [1]